ALLOGENIC TRANSPLANT PATIENTS

Clinical trials for ALLOGENIC TRANSPLANT PATIENTS explained in plain language.

Never miss a new study

Get alerted when new ALLOGENIC TRANSPLANT PATIENTS trials appear

Sign up with your email to follow new studies for ALLOGENIC TRANSPLANT PATIENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug aims to shield vulnerable transplant patients from dangerous gut bacteria

Disease control Recruiting now

This study is testing a new oral drug, SNIPR001, in patients with blood cancers who are getting a stem cell transplant. The goal is to see if it can safely prevent dangerous, antibiotic-resistant E. coli infections in the gut when given alongside standard antibiotic prevention. R…

Matched conditions: ALLOGENIC TRANSPLANT PATIENTS

Phase: PHASE1, PHASE2 • Sponsor: SNIPR Biome Aps. • Aim: Disease control

Last updated Apr 02, 2026 08:42 UTC

ALLOGENIC TRANSPLANT PATIENTS

Get alerted when new ALLOGENIC TRANSPLANT PATIENTS trials appear

New drug aims to shield vulnerable transplant patients from dangerous gut bacteria